Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monotherapy trials: endpoints.

R H Mattson1

  • 1Department of Neurology, Yale University, 333 Cedar Street, 701 LCI, New Haven, CT 06510, USA. richard.mattson@yale.edu

Epilepsy Research
|July 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What constitutes high quality of care for adults with epilepsy?

Neurology·2007
Same author

Long-term seizure outcome in patients initially seizure-free after resective epilepsy surgery.

Neurology·2003
Same author

Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.

Acta neurologica Scandinavica·2003
Same author

GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.

Seizure·2001
Same author

Topiramate rapidly raises brain GABA in epilepsy patients.

Epilepsia·2001
Same author

Human GABA(B) receptor 1 gene: eight novel sequence variants.

Human mutation·2001
Same journal

Comment on "Predictors of surgical outcome in frontal lobe epilepsy: Experience from a single-center cohort in Latin America".

Epilepsy research·2026
Same journal

Response to: "A critical appraisal of principal component analysis of antiseizure medication-induced hostility/aggression and factor analysis of levetiracetam".

Epilepsy research·2026
Same journal

Access to inpatient video-EEG monitoring for patients with frequent seizure-related emergency visits.

Epilepsy research·2026
Same journal

Effect of the ketogenic diet on absence seizures in rats with genetic absence epilepsy.

Epilepsy research·2026
Same journal

Diagnostic accuracy of artificial intelligence models for seizure outcome prediction after epilepsy surgery: A systematic review and meta-analysis.

Epilepsy research·2026
Same journal

Quality assessment of persian epilepsy mobile applications: A systematic review using uMARS and DISCERN.

Epilepsy research·2026
See all related articles

Antiepileptic drug (AED) trials assess drug efficacy and tolerability. Key outcomes include seizure control, adverse effects, and quality of life, guiding treatment recommendations.

Area of Science:

  • Clinical Pharmacology
  • Neurology
  • Biostatistics

Background:

  • Monotherapy antiepileptic drug (AED) trials are crucial for evaluating drug efficacy and tolerability against placebo or other treatments.
  • Standardized outcome measures are essential for interpreting trial results and guiding clinical recommendations.

Purpose of the Study:

  • To outline the optimal design and outcome measures for antiepileptic drug (AED) monotherapy trials.
  • To emphasize the importance of efficacy, tolerability, and quality of life as primary and secondary outcomes in AED trials.

Main Methods:

  • Utilizing time-to-event analysis (life tables) to assess drug continuation rates as a primary efficacy endpoint.
  • Defining clear criteria for treatment continuation and discontinuation based on seizure control and adverse events.

Related Experiment Videos

  • Employing seizure rates, remission rates, and seizure severity assessments to further evaluate efficacy.

    • Main Results:

    • Time of continuation on drug is the most significant outcome for defining treatment success or failure in AED trials.
    • Efficacy is primarily measured by seizure prevention or reduction, with complete seizure control as the ultimate goal.
    • Adverse effects and tolerability are critical secondary outcomes, assessed through incidence, prevalence, frequency, severity, and persistence.

    Conclusions:

    • AED monotherapy trials provide essential data on drug performance, guiding clinical practice and treatment selection.
    • Comprehensive outcome assessment, including efficacy, safety, and quality of life, is vital for a holistic understanding of AEDs.
    • Standardized methodologies in AED trial design ensure reliable and comparable results for evidence-based medicine.